UAB 18106:OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy

Grant

Date/time Interval

  • March 22, 2019 - March 21, 2020

    • Awarded By

    Total Award Amount

  • 26696.00

    • Direct Costs

  • 20535.00

    • Sponsor Award Id

    • Contributor

  • Stringer-Reasor M.D., Erica   Principal Investigator